Abstract
DP IV (CD26) represents an accessory surface molecule playing an important role in the process of activation and proliferation of human lymphocytes. The molecular events mediated by this ectoenzyme are only partly established and the necessity of DP IV enzymatic activity for its signalling capacity has been discussed controversial. Focusing on the putative role of the catalytic domain of this peptidase, it could be shown that inhibition of the catalytic activity can provoke many cellular effects, including induction of tyrosine phosphory-lations and p38 MAP kinase activation as well as suppression of DNA synthesis and reduced production of various cytokines. TGF-β, the production and secretion of which is increased after DP IV inhibition, supposedly mediates the observed suppressive effects by maintaining p27kip expression levels which leads to a cell cycle arrest in G1. Moreover, anti-CD3-induced signalling pathways, including Ca2+ mobilisation, MEK1-, Erk1/2-and PKB-activation, can be strongly affected by DP IV inhibition. Thus, the enzymatic activity or at least the interaction of effectors with the catalytic domain of CD26 seems to be important for crucial functions of this cell surface antigen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dang, N.H., et al., 1990, Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J.Immunol. 144: 4092–4100.
De Meester, I., et al., 1999, CD26, let it cut or cut it down. Immunol. Today 20: 367–375.
Fleischer, B., 1994, CD26: a surfaceprotease involved in T cell activation. Immunology Today 15: 180–184.
Hegen, M., et al., 1993, Enzymatic activity of CD26 (Dipeptidyl-peptidase IV) is not required for its signalling function in T cells. Immunobiol. 189: 483–493.
Hegen, M., et al., 1997, Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. Immunology 90: 257–264.
Hopsu-Havu, V.K., and Glenner, G.G., 1966, A new peptide naphtylamidase hydrolyzing glycylprolyl-naphtylamide. Histochemistry 7: 197–201.
Kähne, T., et al., 1995, Enzymatic activity of DPIV/CD26 is involved in PMA-induced hyperphosphorylation of p561ck. Immunol. Lett. 46: 189–193.
Kähne, T., et al., 1997, In Leukocyte Typing VI. (T. Kishimoto, et. al., eds), Garland Publishing.
Kähne, T., et al., 1998, Earlyphosphorylation events induced by DPIV/CD26-specific inhibitors. Cell Immunol. 189: 60–66.
Kähne, T., et al., 1999, Dipeptidyl peptidase IV: a cell surfacepeptidase involved in regulating T cell growth. Int. J. Mol. Med. 4: 3–15.
Polyak, K., et al., 1994, p27Kipl, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8: 9–22.
Reinhold, D., et al., 1994, Inhibitors of dipeptidyl peptidase IV (DPIV, CD26) specifically suppressproliferation and modulate cytokine production of strongly CD26 expressing U937 cells. Immunobiology 192: 121–136.
Reinhold, D., et al., 1997, Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growthfactor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol. Lett. 58: 29–35.
Schön, E., et al., 1985, The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed. Biochim. Acta 44: K9–K15.
von Bonin, A., et al., 1998, Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol.Rev. 161: 43–53.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Kähne, T., Reinhold, D., Neubert, 2., Born, I., Faust, J., Ansorge, S. (2002). Signal Transduction Events Induced or Affected by Inhibition of the Catalytic Activity of Dipeptidyl Peptidase IV (DP IV, CD26). In: Langner, J., Ansorge, S. (eds) Cellular Peptidases in Immune Functions and Diseases 2. Advances in Experimental Medicine and Biology, vol 477. Springer, Boston, MA. https://doi.org/10.1007/0-306-46826-3_14
Download citation
DOI: https://doi.org/10.1007/0-306-46826-3_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46383-9
Online ISBN: 978-0-306-46826-1
eBook Packages: Springer Book Archive